Wilmington’s Incyte Partners With Natera on Phase 2 Colorectal Cancer Trial Guided by MRD Testing
Article excerpt
Highlighted: the sentence this signal was extracted from
Incyte, the Wilmington, Delaware-based biopharmaceutical company, will use Natera 's Signatera™ blood test to identify patients for a new Phase 2 colorectal cancer (CRC) trial of its investigational immunotherapy, Natera announced on November 10, 2026. Under a clinical collaboration agreement, the trial will evaluate Incyte's INCA33890, an investigational bispecific immunotherapy, in patients whose cancer shows signs of returning before it appears on scans. "Patients with colorectal cancer who remain MRD-positive after surgery and chemotherapy represent a population with substantial unmet need and a significantly elevated risk of recurrence," said Lois Erskine, Vice President and INCA 33890 Global Program Head at Incyte. The study will enroll patients with stage 2 or stage 3 CRC who have completed surgery and adjuvant chemotherapy (ACT), the chemotherapy given after surgery. After ACT, patients will be monitored with Signatera for up to 12 months. Signatera detects molecular residual disease (MRD), small traces of cancer that remain after treatment. Patients who test MRD-positive but show no evidence of cancer on imaging may be eligible to enroll and receive INCA33890. Signatera will also serve as both a primary and secondary endpoint in the trial. Natera's clinical and real-world evidence and its experience designing MRD-guided trials helped inform the study. Natera will...
Keep reading with a free account
The rest of this article, and every signal for Incyte, is in your free account.
